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ackground: To identify bladder cancer specific methylated DNA sequences for the Saudi population in order 
to detect and predict bladder cancer progression.  
Methods: In this study, we analysed DNA methylation levels of 48 tumour suppressor genes loci in 24 bladder 
tissues (19 bladder cancer samples and 5 control samples taken from histologically normal bladders).  DNA 
Methylation analysis was done using Human Tumour Suppressor Genes EpiTect Methyl II Complete PCR Array 
from Qiagen TM. 
Results: We identified significant difference in DNA hypermethylation levels at APC, BRCA1, CDH1, CDH13, 
CDKN2A, DAPK1, ESR1, FHIT, MGMT, RASSF1, SOCS1, TIMP3, TP73, VHL, WIF1 between controls and 
cancerous samples. It was also observed that CADM1 and DKK3 were differentially methylated in non-muscle 
invasive versus muscle invasive bladder cancer samples. Additionally, DNA hypermethylation of ESR1 was 
notified as the novel tumour suppressor gene specific for the Saudi population in bladder cancer.  
Conclusion: Our findings suggest that these aberrant DNA methylation patterns in bladder cancer are disease 
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Bladder cancer (BC) ranked 13th in Saudi population, 
while it is ninth common cancer in the world [1]. Although, 
BC is much less prevalent in this region, but alarmingly it 
ranked first among the genitourinary cancers [2]. Its 
incidence is particularly high in north-western region of 
Saudi Arabia, because of its association with 
schistosomiasis [3]. Although not reported, other risk 
factors associated with the development of BC in the 
Saudi population could be excessive smoking, exposure 
to increased levels of toxic chemicals and petroleum 
products. 
BC can be divided into two groups, Non-Muscle 
Invasive Bladder Cancer (NMBC) and Muscle Invasive 
Bladder Cancer (MBC). Approximately, 80% patients’ 
presents with NMIBC and have good prognosis, 
however, majority of treated cases recur and progress to 
MIBC [4]. Hence, such patients require long term follow 
up with periodic cystoscopy [5]. Although, cystoscopy is 
an essential prognostic and diagnostic tool, but it is 
invasive and levies enormous burden in terms of 
procedural cost in outpatient clinics [6]. Protein based 
biomarkers (NMP22, Fibrin/FDP, BTA) has also been 
introduced as a non-invasive method for early BC 
detection and monitoring, however each lack specificity 
and sensitivity particularly in low grade tumours [7].  
Epigenetic alteration plays an important role in bladder 
carcinogenesis and DNA methylation reveals important 
epigenetic mutations with further downstream effects, 
without altering the DNA sequence [8,9]. BC has 
significantly pronounced differential DNA methylation 
compared to non-urothelial cancer patients. Specifically, 
DNA hypermethylation of CpG dinucleotide at the 
promoter region, a “bladder-specific region,” of tumour 
suppressor genes causing gene suppression is the most 
frequent epigenetic change seen in BC [10,11] 
.Interestingly, these differential DNA methylation 
patterns can also be found as cell free DNA (cfDNA) in 
the body fluids of cancer patients and can be used as 
robust biomarkers to detect and predict cancer 
progression [12]. Alterations in DNA methylation has 
been recognized and localized in at least 50 cancer 
types, these modifications of  DNA without change in 
sequence are heritable and can change gene expression 
[13,14]. Thus, such molecular diagnosis may present as 
a powerful tool for BC detection before it presents 
clinically, especially for types of BCs with better 
outcomes. These studies should not only be able to 
detect the cancerous tissue, but also localize the tissue 
of origin (TOO) in asymptomatic patients. They can also 
be utilized to understand therapeutic response and 
prognosis of BC patients [13,14]. Urine cfDNA is also 
gaining attention recently for diagnosis of BC through full 
void, pellet or supernatant urine. This method is less 
invasive and has better sensitivity than urine cytology 
and FISH, especially in diagnosing earlier stages of BC 
[9,15,16].  
Bladder cancer-related epigenetic alterations is by far, 
studied widely among various populations of BC 
patients. Evidence suggests that these alterations are 
dynamic and respond to environmental influences [17]. 
However, no study to-date has profiled DNA methylation 
of BC patients in Saudi population in spite of ranking top 
on the list among other urogenital cancers. Therefore, in 
this study, we aim to profile methylation pattern of 48 
candidate tumour suppressor genes in normal and 
cancerous bladder tissue among the Saudi population. 
Based on our results, we will be able to reveal distinctive 
methylation patterns between normal and cancerous, 
invasive and non-invasive cancerous bladder tissue, 
specific for the Saudi population. This will later help us to 
recognise a newer molecular biomarker specifically for 
the Saudi population and help us to improve clinical 
decision making and treatment planning in this region. 
Methods 
Tissue Samples  
Fresh samples of cancerous bladder tissue were 
collected from 19 patients during cystoscopy, at King 
Faisal Hospital and Research Centre Urology Clinic, 
before the initiation of any kind of treatment. As control, 
5 corresponding normal appearing tissue samples, 
adjacent to tumour were also obtained for the study. 
Patients with the history of cystitis and tumour other than 
bladder region were excluded. Fragments from each 
tissue sample were embedded in paraffin and stained 
with H&E stain. The clinicopathological parameters were 
confirmed by the pathologist. Tumours were staged 
according to TNM classification system. Detail 
demographic and clinic-pathologic parameters for all the 
samples are listed in Table 1. The collected samples 
were stored at -80oC until use. All samples were 
collected after taking informed consent. Ethical approval 
was obtained from Office of Research (ORA) of King 
Faisal Specialist Hospital and Research Centre 
(KFSHRC). 
Table 1: Summary of Clinical Pathological Data of Tumor and 
Normal Control Samples 
DNA Extraction 
The DNA was extracted as per protocol of the Qiagen 
tissue kit. The quality and quantity of the extracted DNA 
was confirmed by measuring 260/280 ratios on 
spectrophotometer (ND-1000; Nano Drop 
Technologies). 
 Variable Cancer Cases[n=19] Control[n=5] 
Age - - 
Median  60 60 




Male  14 [74%] 4 [80%] 




Invasive [MIBC] 8 [42%] - 




Stage CIS  1 [5.2%] - 
Stage Ta 10 [52.6 %] - 
Stage T1 0 - 
Stage T2 7 [36.8%] - 
Stage T3 0 - 




High grade 12 [63%] - 




Primary 6 [31.5%] - 
Recurrence 13 [68.5%] - 
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Selection of Genes  
The 48 tumour suppressor genes selected for this study 
were selected based on previous studies examining 
DNA methylation markers for diagnosis and prognosis of 
different cancers. Majority of these genes evaluated here 
are implicated in tumorigenesis of BC.  
Methylation PCR Array 
The EpiTect Methyl II PCR Array (Qiagen) was 
performed to evaluate the DNA methylation status at 48 
tumour suppressor gene promoters in 24 samples. The 
EpiTect Methyl II DNA restriction digestion assays were 
used as per Qiagen’s protocol. This method detects the 
remaining input DNA after restriction digestion by 
methylation dependent and methylation sensitive 
enzymes.  Briefly, 4 micrograms of genomic DNA were 
used with 100ul of 5x digestion buffer and RNase-DNase 
free water without enzymes.  This mix was further 
incubated at 37oC with four different treatments 1) DNA 
methylation-dependent restriction enzyme (Md) 2) DNA 
methylation Sensitive restriction enzyme (Ms) 3) 
Restriction enzyme digestion by both Md and Ms 
(Md/Ms) 4) Mock enzyme treatment (Mo).  The remaining 
DNA after digestion in each of the four reactions was 
amplified by real time-PCR using predesigned primers.  
The real time PCR was performed using 7000 Sequence 
Detection System (Applied Bio systems, Foster City, CA, 
USA) using SYBR® Green and CT values were 
recorded. The cycling conditions were 95 ◦C for 10 min 
followed by 40 cycles of 97 ◦C for 15 s and 72 ◦C for 1 
min. SABiosciences Excel-Based Data Analysis was 
performed. This template uses the percent of 
hypermethylated DNA by comparing the amount of DNA 
in each digest with mock digest. This represents the 
fraction of input DNA containing at least two methylated 
CpG sites in the targeted gene region. Differences in 
methylation levels among three groups were noted and 
later use for further statistical evaluation. 
Statistical Analysis 
Descriptive statistics were used to summarize patient 
data and DNA methylation status of 48 genes. Pairwise 
associations followed dichotomous variables defined 
according to presence or absence of tumour, tumour 
invasiveness [non-invasive versus invasive] and 
differentiation grade (low versus high).The association of 
promoter methylation of each gene with outcomes was 
assessed by Mann-Whitney U test with a 5% significance 
level.  SPSS v 20.0 (SPSS – Statistical Package for The 
Social Sciences v20.0, SPSS Inc.) was used for all 
statistical analysis. 
Results 
Clinical Pathological Data of Cancerous Cases and 
Control Samples- 
The cases (n=19) and control (n=5) were well matched 
on age and race. The median age of all cancerous and 
normal patients was 60, with no significant difference. 
However the number of male and females varies in both 
the groups i.e., males were 74% and females 25%. 
Tumour samples were further stratified based on tumour 
staging into NMIBC (58%) and MIBC (42%); and based 
on tumour grading into low grade (7 %) and high grade 
(12 %) (Table 1). Based on pathological staging, most 
common type was non-invasive papillary carcinoma 
(52.6%) among all cancerous tissue samples. 68.5 % of 
the cases were positive with a history of relapse.  
Comparison of Variable Groups 
Clustering results of our tissue sample between 3 paired 
groups [divided according to the presence or absence of 
tumour, tumour invasiveness and differentiation grade] 
showed hypermethylation in all samples. However, 
statistically significant differential gene methylation 
frequency has been noted among few gene loci for each 
of these compared groups (Table 2).   
Regarding the tumour existence, 15 genes (APC, 
BRCA1, CDH1, CDH13, CDKN2A, DAPK1, ESR1, FHIT, 
MGMT, RASSF1, SOCS1, TIMP3, TP73, VHL, and 
WIF1) showed significant difference in DNA methylation 
status in cancerous tissue compared to normal. 
Interestingly, only TP73 showed significantly high 
hypermethylation levels in the cancerous tissue as 
compare to normal with p value = 0.0021 (Table 2). 
However, all the other 14 genes showed lower 
hypermethylation levels in bladder cancerous tissue 
samples with most significant RASSF1, WIF1 and TIMP3 
genes. We also identified one novel tumour suppressor 
gene (ESR1) in this group, which showed significantly 
low hypermethylation levels in bladder cancer tissue 
compared to normal samples. The methylation status of 
the remaining genes in bladder cancer samples did not 
differ significantly from the methylation status of healthy 
controls as shown in Figure 1 (A&B). 
Regarding the tumour invasiveness, only two genes 
(CADM1 and DKK3) were found to demonstrate 
significantly high hypermethylation (p = 0.0277 and 
0.0487 respectively) in patients with MIBC compared to 
NMIBC (Fig 2-A, Table 2). Some genes show higher 
hypermethylation in invasive than non-invasive cancer 
samples, but they do not reach the statistically significant 
threshold (Fig 2). All other genes show less or no change 
in methylation pattern in invasive compared to non-
invasive tissue samples. 
Regarding the tumour grading, no gene was reported 
to have significant methylation difference in comparison 
of low and high grade tumours. 
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Figure 1: Histogram A & B showing DNA methylation profile 
between normal and cancerous bladder tissue among the Saudi 
population.  Mann-Whitney Test was performed to determine the 
association between normal and cancerous bladder tissue samples with 
a 5% significance level. * and ** denotes p value < 0.05 and 0.01 
respectively. 
 
Figure 2: Histogram A & B showing DNA methylation profile 
between MIBC and NMIBC among the Saudi population. Mann-
Whitney Test was performed to determine the association between 
invasive and non-invasive bladder cancer samples with a 5% 
significance level. * and ** denotes p value < 0.05 and 0.01 
respectively. 
Discussion 
In our study, significant difference in DNA 
hypermethylation levels was observed at APC, BRCA1, 
CDH1, CDH13, CDKN2A, DAPK1, ESR1, FHIT, MGMT,  
 
Table 2: Genes showing Statistically Significant Evidence of Differential 
Methylation Among Non-Invasive, Invasive Ca & Controls 
 
RASSF1, SOCS1, TIMP3, TP73, VHL, WIF1 between 
controls and cancerous samples. 
It was also observed that CADM1 and DKK3 are 
differentially methylated in NMIBC versus MIBC 
samples. In contrast, no significant difference in DNA 
methylation levels at any gene promoter was found to be 
associated with tumour grade. 
Evidence suggests that these altered DNA methylation 
patterns are dynamic and respond to environmental 
influences [17]. To our knowledge, this is the first study 
which has analysed the methylation patterns in BC, using 
a panel of 48 candidate genes loci in 19 bladder cancer 
patients from the Saudi population. 
Many studies have identified RASSF1 and WIF1 as 
candidate tumour suppressor gene which epigenetically 
gets inactivated during various human carcinogenesis 
[18]. Their hypermethylation has also been reported in 
BC which is significantly higher than healthy controls 
[19]. Recently, the RASSF1 gene has been highlighted 
as most commonly hypermethylated genes in tumours 
[20]. Likewise, our study reveals the significant 
difference in hypermethylation patterns in both these 
Genes  
Ca Vs. Controls  Invasive Vs. Non-invasive  










APC 64.77 70.12 0.0179 64.62 65.15 - 
BRCA1 62.62 68.99 0.0255 62.44 63.1 - 
CDH1 72.78 77.72 0.0326 72.63 73.16 - 
CDH13 72.22 77.34 0.0396 72.06 72.62 - 
CDKN2A 68.28 73.58 0.0335 68.11 68.69 - 
DAPK1 68.4 74.18 0.049 68.2 68.87 - 
ESR1 66.07 71.87 0.0435 65.88 66.53 - 
FHIT 64.79 70.91 0.0265 64.61 65.25 - 
GSTP1 73.32 75.62 - 73.21 73.55 - 
MGMT 68.19 74.93 0.0374 68 68.66 - 
MLH1 67.72 72.08 - 67.58 68.08 - 
NEUROG1 72.99 78.37 - 72.79 73.47 - 
PDLIM4 79.78 84.44 - 79.61 80.2 - 
PTEN 68.22 70.89 - 68.08 68.55 - 
RARB 68.57 73.28 - 68.4 68.97 - 
RASSF1 68.65 75.29 0.012* 68.47 69.1 - 
RUNX3 81.03 85.74 
 
80.86 81.44 - 
SOCS1 68.77 75.84 0.0196 68.57 69.28 - 
TIMP3 69.61 74.58 0.0464 69.44 70.01 - 
TP73 93.64 87.16 0.0021* 93.72 93.39 - 
VHL 64.51 70.53 0.0448 64.32 65 - 
WIF1 70.58 78.25 0.0143* 70.37 71.11 - 
ABL1 25.26 17.63 - 18.99 31.31 - 
AKT1 59.57 49.63 - 63.38 54.98 - 
ATM 56.19 47.76 - 60.1 51.89 - 
BCL2 74.49 51.18 - 71.75 78.2 - 
BCR 71.77 62.59 - 71.39 72.11 - 
BIRC5 60.89 48.34 - 62.28 59.43 - 
BRAF 54.88 49.74 - 52.93 55.87 - 
BRCA2 55.29 50.45 - 58.53 51.13 - 
CADM1 64.26 51.92 - 71.54 57.18 0.0277 
CAV1 57.61 47.63 - 57.42 57.19 - 
CCND1 55.79 47.49 - 60.61 50.25 - 
CCND2 63.55 55.61 - 69.14 58.62 - 
CD44 60.36 50 - 61.56 58.91 - 
CDKN1A 63.64 54.49 - 67.21 59.51 - 
CDKN1B 61.23 52.04 - 62.5 59.74 - 
CDKN1C 58.13 49.35 - 62.68 52.74 - 
CDKN2B 63.04 52.58 - 63.58 62.41 - 
CDKN3 51.45 34.46 - 53.57 47.95 - 
CDX2 74.15 56.74 - 78.84 69.5 - 
CHFR 62.21 49.76 - 63.99 59.83 - 
CTNNB1 58.66 50.02 - 60.43 55.95 - 
DIRAS3 81.76 75.02 - 82.19 81.37 - 
DKK3 67.25 51.79 - 74.33 60.51 0.0487 
DLC1 59.77 50.88 - 64.8 54.56 
 
Significant P value = <  
0.05 
- - - - - 
* Highly Significant  - - - - - 
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genes between cancerous and control samples; 
however the hypermethylation levels were much higher 
in controls which was an unexpected finding. As the 
controls were taken from the adjacent normal tissue of 
matched cancerous samples. This suggests that 
genomic changes and DNA methylation changes in 
bladder tissue  may occur before the morphological 
changes [21]. Aberrant methylation patterns in the 
control samples suggest to be a characteristic of a 
premalignant lesion as bladder cancer is a multifocal 
tumour with high recurrence index [22]. A genome-wide 
DNA methylation study on upper urinary tract urothelial 
cancer also noted increased DNA methylation in non-
cancerous cells at numerous CpG sites without 
histological changes, suggesting that field effect of 
tumour agents can induce transformation in 
neighbouring cells [23]. Thus, this verifies the hypothesis 
that DNA methylation changes in cancers may pre-exists 
in normal looking cells and it can be beneficial for the 
early detection of BC even in the Saudi population.   
TP73 gene was found to be significantly 
hypermethylated tumour suppressor in this study. This 
gene belongs to the TP53 family of transcription factor 
genes and it leads to apoptosis in response to DNA 
damage [24]. TP73 has been particularly well studied in 
breast tumours [25]. Overexpression of TP73 has also 
been reported in bladder and prostate cancers [26]. 
Interestingly, we showed higher levels of 
hypermethylation at this gene locus among BC samples 
of Saudi origin compared to controls.   
TIMP3 gene, encodes the inhibitor of the matrix 
metalloproteinase, a peptidase involved in degradation 
of the extracellular matrix [27]. Significant difference in 
the hypermethylation status of this gene locus found in 
this study can be considered a significant finding in 
relation to Saudi Arabia, since previous reports 
suggested links between hypermethylation of TIMP3 
gene with schistosome-infected bladder cancer [28].  
Although, our results have confirmed previous studies 
showing varied hypermethylation frequencies among 
different genes in BC. Interestingly, one novel tumour 
suppressor genes ESR1 is also notified showing 
significant difference in DNA hypermethylation status in 
BC tissue samples as compared to controls. 
Hypermethylation of this gene has not been reported 
earlier in the literature in relation to BC and can be 
considered specific for the Saudi population. ESR1 
encodes the estrogen receptor 1, this protein influences 
the growth and differentiation function of different tissues 
in response to estrogen. This gene shows high frequency 
of genetic variation in many types of human malignant 
tumours especially in breast tissues [29] but no link with 
BC was reported earlier. 
Several studies have identified methylated genes and 
panel of loci that are associated with the bladder cancer 
invasion, such as IPF1, GALR1, TAL1, PENK, TJP2, 
HOXB2, RASSF1A and RARβ genes [30]. Interestingly, 
current study shows for the first time that differential 
hypermethylation of CADM1 and DKK is associated with 
MIBC.  
The CADM1 gene (also known as TSLC1 or IGSF4) 
codes for cell-to-cell adhesion in Ca+ independent 
manner. It has been generally investigated as a tumour-
suppressor gene in prostate, oesophageal, 
nasopharyngeal, non-small cell lung and cervical 
cancers [31,32]. CADM1 is down regulated frequently in 
many cancers via promoter hypermethylation [33]. 
However, relevance of its hypermethylation in BC 
prognosis is not well known. A significant increase in 
DNA methylation levels of CADM1 among MIBC 
observed in our study supports its possible down 
regulation in invasive bladder tumours.  
DKK3 encodes a protein that is a member of the 
dickkopf family. The secreted protein through its 
interactions with the Wnt signalling pathway is involved 
in embryonic development. Variety of cancer cell lines 
have shown decreased expression of this genes and it 
may function as tumour suppressor [34]. It has been 
shown previously that hypermethylation of DKK3 in 
cervical cancer cell lines can lead to activation of Wnt/β-
catenin pathway and increased tumorigenesis [35]. 
Therefore, it would be interesting to decipher its role in 
invasive bladder cancer. A study with larger sample size 
can determine its value in prognosticating BC in the 
Saudi population. 
There have also been studies identifying the role of 
DNA methyltransferase 3B (DNMT3B) in the 
tumourigenesis of BC through microRNA (miR)-34a 
promoter methylation, through its downregulation [36]. 
Matrix Metalloproteinase 11 (MMP11) is also a 
differentially expressed gene in BCs due to its promoter 
hypomethylation. MMPs are extracellular enzymes that 
break down the extracellular matrix [37]. Methylation 
status of genes such as SOX-1, IRAK3 and LI-MET were 
shown to be more useful in determining tumour 
progression than cystoscopy. Furthermore, 
hypermethylated TIG1, GSTP1 and APC were 
associated with worse survival rates [14]. 
Hypomethylation, and consequently downregulation of 
the promoter region of the AJAP1 gene (which codes for 
adherens junction-associated protein 1) by the ten-
eleven translocation 1 (TET1), indicates poor prognosis 
due to subsequent activation of the β-catenin signalling 
pathway leading to BC pathogenesis [38].  
Recently, it has been shown that cell free DNA in the 
urine can be used as a sensitive and specific biomarker 
for detection of bladder cancer [39,40]. Studies from 
Rose et al and Wu et al have demonstrated several DNA 
methylation based urinary biomarkers including ITIH5, 
ECRG4, HOXA9, PCDh17, POU4F2 and ONECUT2  
can be used for diagnosis of bladder cancer [39,40]. 
In conclusion, in this study we have identified 
distinctive genes that show evidence of differential 
methylation between cancerous and normal tissue, non-
invasive and invasive cancer tissue specific for the Saudi 
population. This is  a pilot study where we were able to 
screen DNA methylation of status of genes which can be 
used as potential biomarkers for BC diagnosis and 
prognosis  However, larger studies on BC-associated 
changes in DNA methylation are required for developing 
sensitive and specific biomarkers for diagnosis and 
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prediction of the disease. Recent studies have shown 
that cell free tumour derived DNA in urine and blood 
samples can be easily detected using specific DNA 
methylation patterns.  Since the DNA methylation 
patterns are tumour specific and population specific so 
identification of DNA methylation patterns specific to 
Saudi population of bladder cancer is an important first 
step to develop distinct DNA methylation-based 
biomarkers specific for the Saudi population. 
This is a pilot study to screen out potential DNA 
methylation markers which can used in future for 
detection and prognosis of bladder cancer on a large 
representing sample size of Saudi population. As we 
were screening 48 tumor suppressors we needed large 
quantity of good quality DNA (4 microgram) from our 
biopsy samples to conduct our experiments, which was 
not available from small size of the normal bladder 
biopsies. This is the reason we had only 5 control 
samples taken from the adjacent normal tissues of the 
bladder cancer patients.    However, we were able to 
compare the DNA methylation status for 48 genes in 
three different group which was quite extensive and 
conducted for the first time in this region. We will utilise 
data from this study to select significantly differentially 
methylated genes with larger sample size to develop 
sensitive and specific tumour markers for BC in future. 
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